2-(2-硫代吗啉-4-基乙基)异吲哚-1,3-二酮 | 118599-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(2-硫代吗啉-4-基乙基)异吲哚-1,3-二酮
• 英文名称: N-(2-Thiomorpholinoethyl)phthalimide
• 英文别名: 2-[2-(Thiomorpholin-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione；2-(2-thiomorpholin-4-ylethyl)isoindole-1,3-dione
• CAS: 118599-18-1
• 化学式: C₁₄H₁₆N₂O₂S
• 分子量: 276.359
• InChiKey: NEBRDMZOIILQAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-硫代吗啉-4-基乙基)异吲哚-1,3-二酮 在 potassium carbonate 、 一水合肼 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-Phenyl-3-<2-(thiomorpholino)ethyl>traizene
  参考文献：
  名称：

  Preparation and antitumor activity of additional mitomycin A analogs

  摘要：

  On the basis of qualitative structure-activity relationships developed in the preceding article, a series of 32 new mitomycin A analogues were prepared and tested in antitumor screens. Seven of them gave greater prolongation of life (ILS) than mitomycin C in the mouse P388 leukemia assay. They included examples with 7-O substituents such as cyclic ethers and nitrogen heterocycles. A Hansch analysis was attempted with log P and MR as the independent variables, but no statistically significant correlation could be made. Seven compounds, chosen mainly for their good potency (MED), were tested in the subcutaneous B16 melanoma assay in mice and four of them showed greater ILS than mitomycin C.

  DOI：

  10.1021/jm00123a036
• 作为产物：
  描述：

  硫代吗啉 、 N-(2-溴乙基)邻苯二甲酰亚胺 在 sodium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以24%的产率得到2-(2-硫代吗啉-4-基乙基)异吲哚-1,3-二酮
  参考文献：
  名称：

  Preparation and antitumor activity of additional mitomycin A analogs

  摘要：

  On the basis of qualitative structure-activity relationships developed in the preceding article, a series of 32 new mitomycin A analogues were prepared and tested in antitumor screens. Seven of them gave greater prolongation of life (ILS) than mitomycin C in the mouse P388 leukemia assay. They included examples with 7-O substituents such as cyclic ethers and nitrogen heterocycles. A Hansch analysis was attempted with log P and MR as the independent variables, but no statistically significant correlation could be made. Seven compounds, chosen mainly for their good potency (MED), were tested in the subcutaneous B16 melanoma assay in mice and four of them showed greater ILS than mitomycin C.

  DOI：

  10.1021/jm00123a036

文献信息

• Novel thiourea derivatives and the pharmaceutical compositions containing the same
  申请人：Suh Ger Young

  公开号：US20080064687A1

  公开（公告）日：2008-03-13

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为vanilloid受体（VR）的调节剂，并包含相应的药物组合物。作为与vanilloid受体活动相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了一种用于预防或治疗这些疾病的药物组合物。
• Thiourea derivatives and the pharmaceutical compositions containing the same
  申请人：Pacific Corporation

  公开号：US08071650B2

  公开（公告）日：2011-12-06

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新的硫脲衍生物，作为vanilloid受体（VR）的调节剂，以及含有该衍生物的药物组合物。作为与vanilloid受体活动相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病、神经损伤、糖尿病性神经病、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病。本发明提供了一种预防或治疗这些疾病的药物组合物。
• 6-substituted mitomycin analogs
  申请人：UNIVERSITY PATENTS, INC.

  公开号：EP0324109A2

  公开（公告）日：1989-07-19

  Novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula V, wherein: Y is hydrogen or lower alkyl; and X is a radical of the formula -O-R, wherein R is: N,N-di(hydroxy lower alkyl)amino lower alkyl, or tri-lower alkoxy silyl lower alkyl, or cyclo lower alkyl, or halo substituted lower alkoxy lower alkyl, or tetrahydro pyranyl, or carboethoxy lower alkyl, or 1-lower alkyl pyrrolidinyl lower alkyl, or N-pyrrolidinyl lower alkyl, or 1-lower alkyl pyrrolydinyl, or dioxanyl, or hydroxy lower alkenyl, or hydroxy lower alkyl thio lower alkyl thio lower alkyl, or dioxanyl lower alkyl, or lower alkyl thio lower alkyl, or phenyl thio lower alkyl, or phenoxy lower alkyl, or thiophenyl lower alkyl, or 1-lower alkyl piperidyl, or alkyl carbonyl amino alkyl, or N-­piperidyl lower alkyl, or lower alkoxy lower alkyl or lower alkyl thio hydroxy lower alkyl, or 1-lower alkyl N-­piperazinyl lower alkyl, or N-thiomorpholinyl lower alkyl.

  治疗动物肿瘤性疾病状态的新方法，该方法包括施用治疗有效量的式 V 化合物、 其中Y 是氢或低级烷基；X 是式 -O-R 的基团，其中 R 是： N,N-二(羟基低级烷基)氨基低级烷基，或三低级烷氧基硅基低级烷基，或环低级烷基，或卤代低烷氧基低级烷基，或四氢吡喃基，或羧氧基低级烷基，或 1-吡咯烷基低级烷基，或 N-吡咯烷基低级烷基，或 1-吡咯烷基低级烷基，或二噁烷基，或羟基低级烯基，或羟基低级烷基硫代低级烷基硫代低级烷基、或二噁烷基低级烷基，或低级烷基硫代低级烷基，或苯基硫代低级烷基，或苯氧基低级烷基，或噻吩基低级烷基，或 1-低级哌啶基烷基，或烷基羰基氨基烷基，或 N-哌啶基低级烷基，或低级烷氧基低级烷基，或低级烷基硫代羟基低级烷基，或 1-低级哌嗪基低级烷基，或 N-硫代吗啉基低级烷基。
• SAMI, SALAH M.;REMERS, WILLIAM A.;BRADNER, WILLIAM T., J. MED. CHEM., 32,(1989) N, C. 703-708
  作者：SAMI, SALAH M.、REMERS, WILLIAM A.、BRADNER, WILLIAM T.

  DOI：——

  日期：——
• US5023253A
  申请人：——

  公开号：US5023253A

  公开（公告）日：1991-06-11